Valitor presents multiple preclinical datasets on the potential of its innovative anti-vegf therapy dosed twice yearly for wet amd at the association for research in vision and ophthalmology (arvo) annual meeting

-vltr-559, a long-acting anti-vegf therapy, could reduce dosing frequency for the treatment of wet amd to twice-yearly, as compared to every eight to twelve weeks for standard-of-care  anti-vegfs -vltr-559 shown to be more durable, while maintaining potency and a similar, clean safety profile in preclinical models
AMD Ratings Summary
AMD Quant Ranking